Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is expected to experience significant growth potential in the future due to the commercialization of its three products, Afrezza, Furoscix, and V-Go. The company also has multiple near-term catalysts, including the May 29 Afrezza pediatric approval and the FDA approval for the Furoscix ReadyFlow autoinjector on July 26, 2026. With a strong balance sheet and potential for increased sales and partnerships, the company's stock outlook appears promising.

Bears say

MannKind is facing significant risks to achieving its current price target due to potential commercial execution challenges, clinical trial setbacks, regulatory hurdles, and dependence on a larger partner for the commercialization of its key products. The company has also announced a potential second product in collaboration with United Therapeutics, which could provide significant revenue upside, but this is a long-term opportunity that may face delays and uncertainties. The current valuation is based on optimistic future revenue expectations, and any setbacks could impact the company's stock performance.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.